AI assistant
BIO-TECHNE Corp — Director's Dealing 2021
Feb 9, 2021
30718_dirs_2021-02-09_1aa053ea-c9b8-44b5-a798-cb58ecbbd2b1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-02-05
Reporting Person: Eansor Norman David (President-Protein Sciences)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-05 | Common Stock | M | 14114 | $106.59 | Acquired | 15432 | Direct |
| 2021-02-05 | Common Stock | M | 18819 | $106.59 | Acquired | 34251 | Direct |
| 2021-02-05 | Common Stock | S | 6000 | $378.2871 | Disposed | 28251 | Direct |
| 2021-02-05 | Common Stock | S | 4500 | $379.6249 | Disposed | 23751 | Direct |
| 2021-02-05 | Common Stock | S | 12833 | $380.497 | Disposed | 10918 | Direct |
| 2021-02-05 | Common Stock | S | 2900 | $381.5155 | Disposed | 8018 | Direct |
| 2021-02-05 | Common Stock | S | 3700 | $382.6043 | Disposed | 4318 | Direct |
| 2021-02-05 | Common Stock | S | 1900 | $384.1518 | Disposed | 2418 | Direct |
| 2021-02-05 | Common Stock | S | 1100 | $385.5918 | Disposed | 1318 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-05 | Stock Options (Right to Buy) | $106.59 | M | 14114 | Disposed | 2023-08-18 | Common Stock (14114) | Direct |
| 2021-02-05 | Stock Options (Right to Buy) | $106.59 | M | 18819 | Disposed | 2023-08-18 | Common Stock (18819) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $125.05 | 2024-08-09 | Common Stock (11982) | 11982 | Direct |
| Stock Options (Right to Buy) | $125.05 | 2024-08-09 | Common Stock (15976) | 15976 | Direct |
| Restricted Stock Units | $ | Common Stock (2537) | 2537 | Direct | |
| Stock Options (Right to Buy) | $177.32 | 2025-08-08 | Common Stock (13550) | 13550 | Direct |
| Stock Options (Right to Buy) | $177.32 | 2025-08-08 | Common Stock (18066) | 18066 | Direct |
| Restricted Stock Units | $ | Common Stock (3151) | 3151 | Direct | |
| Stock Options (Right to Buy) | $190.41 | 2026-08-07 | Common Stock (15948) | 15948 | Direct |
| Stock Options (Right to Buy) | $190.41 | 2026-08-07 | Common Stock (21265) | 21265 | Direct |
| Restricted Stock Units | $ | Common Stock (2575) | 2575 | Direct | |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (11488) | 11488 | Direct |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (15318) | 15318 | Direct |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (24975) | 24975 | Direct |
| Stock Options (Right to Buy) | $267.87 | 2027-08-05 | Common Stock (24975.0) | 24975.0 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $378.00 to $378.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $379.03 to $380.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.065 to $381.055, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.095 to $382.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $382.26 to $383.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $383.93 to $384.39, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.415 to $385.77, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F9: Fully exercisable.
F10: Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
F11: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F12: Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F16: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
F17: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021
F18: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.